Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Mykhailo Ihnatenko
Mykhailo Ihnatenko

Humacyte extends Symvess shelf life to 36 months after FDA authorization

Humacyte extends Symvess shelf life to 36 months after FDA authorization
Symvess shelf life extended to 36 months

Humacyte announced that the U.S. Food and Drug Administration has authorized an extension of the shelf life for Symvess, its acellular tissue engineered vessel, to 36 months.

The company stated that this increase in shelf life maintains the same storage requirements and supports hospitals in their preparedness and logistical planning. Symvess is used in vascular procedures, and this regulatory development could streamline inventory management for healthcare providers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Not Satoshi: Who created Bitcoin’s logo?
  • By Olena Litvinenko
  • 6 hours ago
Not Satoshi: Who created Bitcoin’s logo?
Editors' Picks
Ryanair tightens its belt: How rising fuel prices threaten the budget airline
  • By Eugene Komchuk
  • 10 hours ago
Ryanair tightens its belt: How rising fuel prices threaten the budget airline
Editors' Picks
How German metalworkers’ strikes are testing Europe’s industrial strength
  • By Dmytro Kharkov
  • 12 hours ago
How German metalworkers’ strikes are testing Europe’s industrial strength
Editors' Picks
All Editors' Top Picks

Latest Humacyte News

University of Texas Medical Branch selects Symvess for surgical advances, Humacyte reports
  • By Alena Volkova
  • 31.10.2026
University of Texas Medical Branch selects Symvess for surgical advances, Humacyte reports
Companies
#Humacyte
Humacyte conducts first Symvess procedure in Oklahoma
  • By Yulia Slavina
  • 28.10.2026
Humacyte conducts first Symvess procedure in Oklahoma
Companies
#Humacyte
V012 clinical trial from Humacyte targets improved dialysis access for women
  • By Elena Nikulina
  • 23.10.2026
V012 clinical trial from Humacyte targets improved dialysis access for women
Companies
#Humacyte
All Humacyte News
  • Olena Litvinenko
  • 6 hours ago
Not Satoshi: Who created Bitcoin’s logo?
  • Eugene Komchuk
  • 10 hours ago
Ryanair tightens its belt: How rising fuel prices threaten the budget airline
  • Dmytro Kharkov
  • 12 hours ago
How German metalworkers’ strikes are testing Europe’s industrial strength
  • Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
  • Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
  • Eugene Komchuk
  • 15 min ago
Chart drop categories range from normal pullback to crisis, Steve Burns notes
  • Ksenia Gerey
  • 19 min ago
Turner Novak: WSJ questioned Adyen's legitimacy when it was backed by early investor
  • Elena Nikulina
  • 20 min ago
U.S. equities outperformed Germany and Japan sevenfold since 2001, Kelly Evans notes
  • Eugene Komchuk
  • 34 min ago
Craig Shapiro: October SLOOS shows credit slowdown driven by weaker demand
  • Yulia Slavina
  • 45 min ago
SpaceX announces significant investment in Louisiana, Mario Nawfal notes
Top News
  • Ivan Andriyenko
  • 4 hours ago
Oil plunges more than 6% as hopes for an end to Iran war grow
Oil plunges more than 6% as hopes for an end to Iran war grow
  • Jose Antonio Gastelum
  • 6 hours ago
Morgan Stanley downgrades Coinbase and cuts price target by more than half
Morgan Stanley downgrades Coinbase and cuts price target by more than half
  • Hanna Syniavska
  • 8 hours ago
SpaceX explores Boost Mobile deal to enter U.S. wireless market
SpaceX explores Boost Mobile deal to enter U.S. wireless market
  • Igor Krasulya
  • 9 hours ago
Alphabet returns to euro bond market despite disappointing earnings
Alphabet returns to euro bond market despite disappointing earnings
  • Ivan Andriyenko
  • 10 hours ago
Gold climbs above $3,900 as bargain hunters return after October rout
Gold climbs above $3,900 as bargain hunters return after October rout
Live News
  • Eugene Komchuk
  • Now
Binance hackers convert stolen Solana into Bitcoin
  • Andrey Mastykin
  • Now
Wall Street futures climb as investors await Apple earnings and U.S. elections
  • Mykhailo Ihnatenko
  • Now
AMD stock eyes $528 as earnings risk raises volatility
  • Anton Kharitonov
  • Now
EUR/USD struggles to sustain recovery as eurozone risks persist
  • Eugene Komchuk
  • Now
Hong Kong launches 24/7 settlement for tokenized assets
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers